These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 22041704)

  • 1. [Comparison in dissolution behavior of ethical and over-the counter scopolamine butylbromide].
    Suzuki I; Miyazaki Y; Uchino T; Kagawa Y
    Yakugaku Zasshi; 2011; 131(11):1645-51. PubMed ID: 22041704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Evaluation of Dissolution Profiles of Famotidine from OTC Drugs].
    Saito Y; Adachi N; Kato M; Nadai M
    Yakugaku Zasshi; 2018 Jun; 138(6):843-851. PubMed ID: 29593173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differing disintegration and dissolution rates, pharmacokinetic profiles and gastrointestinal tolerability of over the counter ibuprofen formulations.
    Bjarnason I; Sancak O; Crossley A; Penrose A; Lanas A
    J Pharm Pharmacol; 2018 Feb; 70(2):223-233. PubMed ID: 29238984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disintegration/dissolution profiles of copies of Fosamax (alendronate).
    Epstein S; Cryer B; Ragi S; Zanchetta JR; Walliser J; Chow J; Johnson MA; Leyes AE
    Curr Med Res Opin; 2003; 19(8):781-9. PubMed ID: 14687450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dissolution Profiles of Generic Products in Dissolution Media Defined by Japanese Guidelines for Bioequivalence Studies.
    Kajiwara E; Kamizato H; Shikano M
    Ther Innov Regul Sci; 2021 Sep; 55(5):1096-1100. PubMed ID: 34097289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Dissolution Similarity Assessment Methods for Products with Large Variations: f
    Yoshida H; Shibata H; Izutsu KI; Goda Y
    Biol Pharm Bull; 2017; 40(5):722-725. PubMed ID: 28458360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dissolution Testing for Bioavailability of Over-the-Counter (OTC) Drugs--a Technical Note.
    Gao Z; Yu L; Clark S; Trehy M; Moore T; Westenberger B; Buhse L; Kauffman J; Bishop B; Velazquez L; Furness S
    AAPS PharmSciTech; 2015 Oct; 16(5):1227-33. PubMed ID: 25680355
    [No Abstract]   [Full Text] [Related]  

  • 8. Evaluating bioequivalence of meloxicam tablets: is in-vitro dissolution test overdiscriminating?
    Jin C; Zhao C; Shen D; Dong W; Liu H; He Z
    J Pharm Pharmacol; 2018 Feb; 70(2):250-258. PubMed ID: 29193077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of zero-order controlled release preparations of nifedipine tablet on dissolution test, together with cost benefit point of view.
    Sakurai M; Naruto I; Matsuyama K
    Yakugaku Zasshi; 2008 May; 128(5):819-26. PubMed ID: 18451631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Criteria for the selection of switch OTC drugs based on patient benefits, efficacy, and safety [II]: Comparing the physicochemical and pharmaceutical properties of brand-name and switch OTC terbinafine hydrochloride cream.
    Takata M; Wada Y; Iwasawa Y; Kumazawa M; Shimokawa KI; Ishii F
    Drug Discov Ther; 2018; 12(4):248-253. PubMed ID: 30224597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Technological and pharmacotherapeutic properties of selected drugs with modified release of diclofenac sodium].
    Kołodziejczyk MK; Kołodziejska J; Zgoda MM
    Polim Med; 2012; 42(2):121-32. PubMed ID: 23016443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In Vitro Dissolution as a Tool for Formulation Selection: Telmisartan Two-Step IVIVC.
    Ruiz Picazo A; Martinez-Martinez MT; Colón-Useche S; Iriarte R; Sánchez-Dengra B; González-Álvarez M; García-Arieta A; González-Álvarez I; Bermejo M
    Mol Pharm; 2018 Jun; 15(6):2307-2315. PubMed ID: 29746133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory Considerations of Bioequivalence Studies for Oral Solid Dosage Forms in Japan.
    Kuribayashi R; Takishita T; Mikami K
    J Pharm Sci; 2016 Aug; 105(8):2270-7. PubMed ID: 27372551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine.
    Jantratid E; Prakongpan S; Amidon GL; Dressman JB
    Clin Pharmacokinet; 2006; 45(4):385-99. PubMed ID: 16584285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of the pharmaceutical quality of marketed enteric coated pantoprazole sodium sesquihydrate products.
    Mostafa HF; Ibrahim MA; Mahrous GM; Sakr A
    Saudi Pharm J; 2011 Apr; 19(2):123-7. PubMed ID: 23960750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thiazides IV: Comparison of dissolution with bioavailability of chlorothiazide tablets.
    Shah VP; Knight P; Prasad VK; Cabana BE
    J Pharm Sci; 1982 Jul; 71(7):822-4. PubMed ID: 7120073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib.
    Tsume Y; Takeuchi S; Matsui K; Amidon GE; Amidon GL
    Eur J Pharm Sci; 2015 Aug; 76():203-12. PubMed ID: 25978875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a Clinically Relevant Dissolution Method for Metaxalone Immediate Release Formulations Based on an IVIVC Model.
    Vuletić L; Khan MZI; Špoljarić D; Radić M; Cetina-Čižmek B; Filipović-Grčić J
    Pharm Res; 2018 Jun; 35(8):163. PubMed ID: 29934663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulatory aspects of drug dissolution from a European perspective.
    Graffner C
    Eur J Pharm Sci; 2006 Nov; 29(3-4):288-93. PubMed ID: 16950606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of dissolution time profiles: No similarity but where is the difference?
    Horkovics-Kovats S
    Eur J Pharm Sci; 2018 Aug; 121():9-15. PubMed ID: 29782910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.